This study looks at whether a daily dietary supplement called HOP Box can improve markers of biological aging and overall health in women. HOP Box contains 19 ingredients selected to support cellular health, metabolism, inflammation, and longevity. Thirty-five women between the ages of 35 and 60 will take the supplement twice a day for 90 days. Researchers will measure changes in biological age using an at-home blood test that analyzes DNA methylation patterns, track sleep quality, heart rate, and heart rate variability using an Oura Ring wearable device, and assess participants' self-reported quality of life using a validated health survey (PROMIS-29). There is no placebo or control group in this pilot study - all participants will receive the supplement and serve as their own comparison over time. The goal is to gather early data on whether HOP Box shows promising health effects in women, which would inform the design of a larger, more rigorous trial in the future.

Inclusion Criteria:

• Women aged 35 to 60 years, English-speaking, and residing in the United States
• Must own an Oura Ring with an active membership and a minimum of 30 days of baseline data
• Willingness to comply with all study procedures, assessments, lifestyle considerations, and follow-ups for the study duration
• Medically stable with no significant health changes in the past three months

Exclusion Criteria:

• Current use of GLP-1 receptor agonists (e.g., semaglutide, liraglutide), SGLT2 inhibitors (e.g., canagliflozin, dapagliflozin, empagliflozin), insulin, metformin, thiazolidinediones, acarbose, alpha-glucosidase inhibitors, or any investigational drug or supplement within the past 30 days
• Current use of NAD+ precursors (nicotinamide riboside, NMN, niacin, NAD+), supplements containing active ingredients already in the HOP Box formulation, high-dose vitamin B12, berberine, alpha-lipoic acid, or other glucose-lowering supplements
• Confirmed diagnosis of Type 1 or Type 2 diabetes, known liver disease (hepatitis, cirrhosis, NAFLD), kidney disease (including CKD or renal impairment), active or recent cancer (within past 5 years, excluding non-melanoma skin cancers), or severe psychiatric/mood disorders (bipolar disorder, schizophrenia, or major depressive disorder requiring hospitalization or intensive psychiatric intervention)
• Known allergy, hypersensitivity, or intolerance to any active or inactive ingredient in the intervention
• Participation in any other clinical trial, wellness intervention, or investigational product study within the 30 days prior to enrollment
• Currently pregnant, breastfeeding, or planning to become pregnant within the next 12 months

Eligible participants must be biological females who self-identify as women, aged 35 to 60 years. The intervention targets sex-specific biological pathways relevant to female health and aging